semaglutide sema  (Novo Nordisk)

Journal: Journal of the Endocrine Society

Article Title: Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism

doi: 10.1210/jendso/bvaf158

Figure Lengend Snippet: Semaglutide modulates glucose metabolism without affecting growth in control-fed juvenile mice. A, Experimental protocol. Created with Biorender.com . B, Fasting glycemia and C, insulinemia. D, Glycemia during an oral glucose tolerance test (OGTT). E, Homeostatic model assessment of insulin resistance (HOMA-IR). F, Body weight over time. G, Cumulative food intake. H, Body size. I, Femur and J, tibia lengths at postnatal day 56 (P56). Weights of K, subcutaneous white adipose tissue (WAT) and L, gastrocnemius muscle at P56. Sema, semaglutide-treated; Veh, vehicle-treated. Data are shown for 1 batch, representative of both, n = 6-7 per group. For food intake, both batches are represented. Data are shown as mean ± 95% CI. * P less than .05; ** P less than .01; **** P less than .0001; ns, not significant.

Article Snippet: They received subcutaneous injections of Sema (Ozempic, Novo Nordisk 0.5 mg injectable solution) at a dose of 30 nmol/kg body weight, or vehicle (Veh; 0.9% NaCl), twice weekly until postnatal day 56 (P56).

Techniques: Control

Journal: Journal of the Endocrine Society

Article Title: Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism

doi: 10.1210/jendso/bvaf158

Figure Lengend Snippet: Semaglutide further impairs linear growth and alters body composition in stunted juvenile mice. A, Experimental protocol. Created with Biorender.com . B, Body size. C, Femur and D, tibia lengths at postnatal day 56 (P56). E, Body weight over time. F, Cumulative food intake. Somatotropic axis markers at P56: G, serum insulin-like growth factor 1 (IGF-1) concentration; H, liver Igf1 expression; I, liver IGF-1 concentration; and J, liver Ghr expression. Muscle K, Igf1r expression and L, phosphorylated protein kinase B (Akt) (S473) to total Akt ratio measured by Western blot and normalized to total protein content. Relative weights of M, subcutaneous white adipose tissue (WAT) and N, gastrocnemius muscle at P56. Sema, semaglutide-treated; Veh, vehicle-treated. Data are shown for 1 batch, representative of both, n = 7-8 per group. For food intake, both batches are represented. Data are shown as mean ± 95% CI. * P less than .05; ** P less than .01; **** P less than .0001; ns, not significant.

Article Snippet: They received subcutaneous injections of Sema (Ozempic, Novo Nordisk 0.5 mg injectable solution) at a dose of 30 nmol/kg body weight, or vehicle (Veh; 0.9% NaCl), twice weekly until postnatal day 56 (P56).

Techniques: Concentration Assay, Expressing, Western Blot

Journal: Journal of the Endocrine Society

Article Title: Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism

doi: 10.1210/jendso/bvaf158

Figure Lengend Snippet: Semaglutide alters energy metabolism gene expression in metabolically active tissues in stunted juvenile mice. A, Volcano plot showing differential gene expression in the liver of stunting-inducing diet–fed juveniles treated with semaglutide (N = 5) vs vehicle (N = 4). Relative expression of energy metabolism-related genes in B, brown adipose tissue (BAT); C, subcutaneous adipose tissue; and D, gastrocnemius muscle. The reference genes used to normalize gene expression are: Rpl32 and Rsp18 for BAT and white adipose tissue (WAT); Gapdh and Tbp for muscle. Sema, semaglutide-treated; Veh, vehicle-treated. Data are shown for 1 batch, representative of both, n = 7-8 per group. Data are shown as mean ± 95% CI. * P less than .05; ** P less than .01; **** P less than .0001.

Article Snippet: They received subcutaneous injections of Sema (Ozempic, Novo Nordisk 0.5 mg injectable solution) at a dose of 30 nmol/kg body weight, or vehicle (Veh; 0.9% NaCl), twice weekly until postnatal day 56 (P56).

Techniques: Gene Expression, Metabolic Labelling, Expressing